Karo Pharma AB (publ) (KARBF)
Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic
Karo Pharma AB (publ) (KARBF) is a publicly traded company in the Healthcare sector. Latest price: $5.25. Market cap $1.52B. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Earnings
Proprietary Signals
About Karo Pharma AB (publ)
Headquartered in Stockholm, Sweden, Karo Pharma AB (publ) specializes in the development and commercialization of both prescription pharmaceuticals and over-the-counter (OTC) health products. These offerings reach pharmacies and retail sectors across numerous global markets, including its home country of Sweden, the Nordic region (Norway, Denmark, Finland), major European economies (France, Germany, Italy), the wider European continent, the United States, and approximately 90 other countries worldwide. The European and Nordic markets represent a particularly strong focus for the company. Karo Pharma boasts a diverse portfolio spanning several health categories. For skin health, prominent brands include Remescar, Locobase, Decubal, and indy beauty. Its intimate health segment features Pevaryl, Multi Gyn, Asan, and Selexid, while foot care is addressed through brands such as Pevaryl, CCS, Nailner, and wortie. The company also provides relief for pain, coughs, and colds under brand names like Paracet, Ibux, Mollipect, and Viruseptin. Essential prescription drugs are marketed under the Burinex, Centyl, Kaleorid, and Lithionit labels. Furthermore, a range of wellness products is availa…
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap